Welcome to our dedicated page for Propanc Bio SEC filings (Ticker: PPCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Propanc Biopharma, Inc. (PPCB) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures, including registration statements, annual and quarterly reports, and current reports on material events. As a Delaware-incorporated, Nasdaq-listed biopharmaceutical company, Propanc uses these filings to describe its proenzyme-based oncology platform, financial condition, capital structure, and key agreements.
Through documents such as the Form S-1 registration statement and periodic reports, readers can review detailed information about Propanc’s business focus on recurrent and metastatic cancer, its lead product candidate PRP, and its status as a pre-revenue development-stage enterprise. These filings discuss risk factors, use of proceeds from offerings, and the scientific and clinical context for PRP and the company’s broader pipeline, including the recombinant follow-on candidate Rec-PRP.
Current reports on Form 8-K are particularly relevant for tracking financing and corporate actions. Recent 8-K filings describe Propanc’s entry into a Securities Purchase Agreement with Hexstone Capital LLC, the creation and designation of Series C Preferred Stock, and the issuance of preferred shares and warrants in a private placement of up to $100 million. These filings outline conversion terms, ownership limitations, and amendments to the company’s certificate of incorporation.
Investors and analysts can also use this page to monitor capital structure and governance changes, including preferred stock designations and uplisting-related disclosures, as well as to cross-reference financial statements and footnotes that detail assets, liabilities, and stockholders’ equity. Real-time updates from EDGAR ensure that newly filed 10-Ks, 10-Qs, 8-Ks, and registration statements are available as they are submitted.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections, highlight key terms in offerings and preferred stock instruments, and help clarify how regulatory disclosures relate to Propanc’s clinical plans, digital asset treasury strategy, and overall risk profile.
Propanc Biopharma, Inc. registers up to 7,000,000 shares of Common Stock for resale by the selling stockholder.
The prospectus states the registered shares include conversions of 100 Initial Shares of Series C Preferred Stock and 9,900 Series C Preferred Stock issuable upon exercise of a Warrant held by Hexstone Capital LLC, and that the Company will not receive proceeds from resales by the selling stockholder. The Warrant exercise price is stated as $10,000 per Series C share; if exercised in full for cash, the Company would receive approximately $99,000,000. The Certificate of Designation includes a 4.99% beneficial ownership limitation (adjustable to 9.99% with notice). Shares outstanding are reported as 15,091,133 before and 22,091,133 after the offering, assuming sale of all registered Shares.
Propanc Biopharma reported a board change. Effective February 20, 2026, long-serving director Dr. Julian Kenyon retired from the Board of Directors to focus on his personal and family life, but he will continue to support the company as a medical advisor.
The Board filled the resulting vacancy the same day by appointing Dr. Ralf Brandt as a new director. Dr. Brandt is an experienced pharmaceutical and oncology research executive with more than thirty years in drug discovery, angiogenesis, and pre-clinical development, and has advanced over 50 compounds to clinical studies.
Propanc Biopharma, Inc. has filed an amended Form S-1 registering the resale of up to 7,000,000 shares of common stock by a single selling stockholder. These shares are issuable upon conversion of 100 outstanding shares and up to 9,900 warrant-exercisable shares of Series C Preferred Stock.
The company will not receive proceeds from the resale, but would receive cash if the Series C warrant is exercised, with potential gross proceeds of approximately
Propanc is a development-stage biotech focused on its lead cancer candidate PRP and discloses substantial doubts about its ability to continue as a going concern, given no revenues, large accumulated deficits and reliance on external financing. The company is a smaller reporting and controlled company, highlighting extensive risks around liquidity, dilution, volatility and speculative nature of its stock.
Propanc Biopharma, Inc. reported results for the three and six months ended December 31, 2025, reflecting continued development-stage operations with no revenue and widening losses. The company posted a net loss of
Cash improved to
The accumulated deficit reached
Propanc Biopharma, Inc. is registering up to 7,000,000 shares of common stock for resale by a single selling stockholder. These shares are issuable upon conversion of 100 outstanding shares of Series C Preferred Stock and up to 9,900 additional Series C Preferred shares underlying a warrant.
The resale relates to a prior $1,000,000 private placement with Hexstone Capital LLC; Propanc will not receive proceeds from stockholder sales, but would receive cash if the $10,000-per-share warrant is exercised, potentially up to $99,000,000. Each preferred share converts at the lesser of $5.00 or 85% of a market-based price, floored at $0.50, subject to 4.99% (optionally 9.99%) beneficial ownership limits. Shares outstanding were 15,091,133 as of January 26, 2026, and would be 22,091,133 if all registered shares are sold. The company is a development-stage oncology business focused on its PRP candidate, reports large recurring losses, has substantial doubt about its ability to continue as a going concern, carries defaulted debt, and warns of significant dilution, volatility, and control by its CEO through preferred stock voting power.
Propanc Biopharma, Inc. is registering up to 2,000,000 shares of common stock for resale by a single selling stockholder. These shares are issuable upon conversion of 100 outstanding shares of Series C Preferred Stock and up to 9,900 additional Series C shares issuable on exercise of a warrant.
The company will not receive proceeds from resale of the registered shares, but would receive cash if the warrant to purchase Series C Preferred Stock is exercised. As of December 15, 2025, 13,364,244 common shares were outstanding, rising to 15,364,244 shares if all registered shares are sold.
Propanc BioPharma reported that on December 31, 2025 it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. This does not cause an immediate delisting. The company has 180 calendar days, until June 30, 2026, to regain compliance, which would occur if its stock closes at or above $1.00 for at least ten consecutive business days. Propanc may qualify for an additional 180‑day period if it meets other listing criteria and notifies Nasdaq it may cure the issue, potentially through a reverse stock split. If compliance is not restored and no extension or appeal succeeds, the stock could be delisted, which the company notes could reduce liquidity, hinder equity financing, limit access to public capital markets, and impair use of equity incentives. The company plans to monitor its bid price and evaluate options.
Propanc Biopharma, Inc. is registering up to 2,000,000 shares of common stock for resale by a single selling stockholder, Hexstone Capital LLC. These shares underlie 100 initially issued shares of Series C Preferred Stock and up to 9,900 additional Series C Preferred shares issuable upon exercise of a warrant. Propanc will not receive any proceeds from the resale, but would receive cash if the warrant is exercised.
Each Series C Preferred share has a stated value of $10,000 and converts into common stock at the lesser of a fixed $5.00 per share or 85% of a market-based price, subject to a 4.99% beneficial ownership cap that may be increased to 9.99% with notice. The company previously raised approximately
Propanc is a development-stage oncology company focused on its lead anti-cancer candidate PRP for pancreatic, ovarian, and colorectal cancers, has no revenue-generating operations and an accumulated deficit, and discloses substantial doubt about its ability to continue as a going concern without additional capital. As of December 15, 2025, it had 13,364,244 common shares outstanding and would have 15,364,244 shares if all registered shares are issued and sold, and it qualifies as both a smaller reporting company and a controlled company under Nasdaq rules.
Propanc Biopharma (PPCB) filed its quarterly report for the three months ended September 30, 2025. The company reported no revenue and a net loss of $4,837,738, compared with a $354,310 loss a year ago. Operating expenses rose to $4,673,564 (from $290,790), driven mainly by administration expenses of $4,598,574, which included non‑cash items such as amortization of prepaid stock-based expenses.
Cash increased to $602,737 from $12,088, helped by financing inflows. The company completed an equity raise on August 18, 2025, selling 1,000,000 shares for $4,000,000 in gross proceeds and receiving approximately $3.3 million net. Total assets were $17,975,681, led by significant prepaid expenses, while total liabilities declined to $3,614,514 as convertible notes and related derivative balances decreased. The filing notes substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 12,806,748 at September 30, 2025, and 13,364,244 as of November 13, 2025.